×
About 1,430 results

ALLMedicine™ Anaplastic Thyroid Cancer Center

Research & Reviews  417 results

Conditional Survival Rate Estimates for Anaplastic Thyroid Cancer Beyond the First Year...
https://doi.org/10.1089/thy.2022.0339
Thyroid : Official Journal of the American Thyroid Associ... Dong W, Okamoto T et. al.

Nov 5th, 2022 - Not Applicable.

Evaluating new treatments for anaplastic thyroid cancer.
https://doi.org/10.1080/14737140.2022.2139680
Expert Review of Anticancer Therapy; Coca-Pelaz A, Rodrigo JP et. al.

Oct 26th, 2022 - Anaplastic thyroid cancer (ATC) is one of the most lethal diseases known to humans with a median survival of 5 months. The American Thyroid Association (ATA) recently published guidelines for the treatment of this dreadful thyroid malignancy. This...

Just a Little Bit of Anaplastic Thyroid Cancer?
https://doi.org/10.1245/s10434-022-12703-w
Annals of Surgical Oncology; Kebebew E

Oct 23rd, 2022 - Just a Little Bit of Anaplastic Thyroid Cancer?|2022|Kebebew E,|

Inhibition of Glycogen Metabolism Induces Reactive Oxygen Species-Dependent Cytotoxicit...
https://doi.org/10.1210/endocr/bqac169
Endocrinology Davidson CD, Tomczak JA et. al.

Oct 15th, 2022 - Anaplastic thyroid cancer (ATC) is one of the most lethal solid tumors, yet there are no effective, long-lasting treatments for ATC patients. Most tumors, including tumors of the endocrine system, exhibit an increased consumption of glucose to fue...

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04759911

Oct 13th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of neoadjuvant selpercatinib in medullary thyroid cancer by objective response rate (ORR) per RECIST (standard Response Evaluation Criteria in Solid Tumors [RECIST]). SECONDARY OBJECTIVES: I. To evalu...

see more →

Guidelines  2 results

2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349723
Thyroid : Official Journal of the American Thyroid Associ... Bible KC, Kebebew E et. al.

Mar 18th, 2021 - Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific ad...

Anaplastic Thyroid Carcinoma, Version 2.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.

Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  45 results

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04759911

Oct 13th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of neoadjuvant selpercatinib in medullary thyroid cancer by objective response rate (ORR) per RECIST (standard Response Evaluation Criteria in Solid Tumors [RECIST]). SECONDARY OBJECTIVES: I. To evalu...

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04675710

Oct 6th, 2022 - PRIMARY OBJECTIVES: I. Demonstrate the efficacy of upfront treatment with neoadjuvant pembrolizumab in combination dabrafenib and trametinib by comparing the complete gross surgical resection rate (R0 or R1 surgical resection) to historical contro...

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT03975231

Sep 30th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and tolerability (maximum tolerated dose [MTD]) of concurrent intensity modulated radiation therapy (IMRT) and BRAF-MEK inhibitors dabrafenib and trametinib in patients with BRAF-mutated anaplastic thyro...

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
https://clinicaltrials.gov/ct2/show/NCT02034981

Sep 8th, 2022 - Twenty cohorts are identified, a cohort being defined as [one pathology, one target alteration] such as [gastric cancer with MET amplification (6%)]. One cohort will be dedicated to miscellaneous, very rare pediatric diseases identified through IN...

Study of AIC100 in Relapsed/Refractory Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04420754

Aug 24th, 2022 - The primary objective of this study is to assess the safety and tolerability and determine the recommended dose of AIC100 for phase 2 study in patients with relapsed/refractory poorly differentiated thyroid cancer and in patients with anaplastic t...

see more →

News  103 results

Clinical Trials Propel New Standards of Care for Thyroid Cancer
https://www.onclive.com/view/clinical-trials-propel-new-standards-of-care-for-thyroid-cancer

Nov 12th, 2022 - Multidisciplinary approaches remain crucial as treatment options rely on expert insights to cover the wide array of thyroid cancer subgroups, according to Alan L. Ho, MD, PhD. The wider the expanse of input, the better chance of expanding and deli...

Secondary RAS Mutations Linked to Thyroid Cancer Severity, Mortality
https://www.medscape.com/viewarticle/983175

Oct 28th, 2022 - Dr Athanasios Bikas MONTREAL — Key genetic mutations secondary to RAS mutations that are common in differentiated thyroid cancer (DTC) strongly correlate with higher risk and more advanced cancers, as well as substantially increased mortality rate...

Tumor Agnostic Approval Targets BRAF V600E–Mutant Disease
https://www.onclive.com/view/tumor-agnostic-approval-targets-braf-v600e-mutant-disease

Aug 15th, 2022 - The FDA has granted accelerated approval to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors. Patients must have bee...

New Tissue-Agnostic Treatment Options Emerge
https://www.onclive.com/view/new-tissue-agnostic-treatment-options-emerge

Aug 2nd, 2022 - The menu of tissue-agnostic oncology drug approvals is growing, generating new treatment options for patients with rare cancers and strengthening the rationale for broad next-generation sequencing (NGS), experts say. In June 2022, the FDA approv...

FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
https://www.onclive.com/view/fda-approves-dabrafenib-plus-trametinib-for-braf-v600e-mutated-unresectable-or-metastatic-solid-tumors

Jun 23rd, 2022 - The FDA has granted an accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors harboring a BRAF V600E mutation w...

see more →

Patient Education  3 results see all →